Fundação Oswaldo Cruz Rondônia FIOCRUZ/RO, Rua da Beira, 7176, Porto Velho, 76812-245, Brazil.
Programa de Pós-Graduação em Biologia Experimental, Universidade Federal de Rondônia e Fundação Oswaldo Cruz Rondônia - UNIR/FIOCRUZ/RO, 76801-974, Porto Velho, Brazil.
Sci Rep. 2023 Jul 26;13(1):12073. doi: 10.1038/s41598-023-37756-z.
Hepatitis Delta is a disease caused by exposure to hepatitis B (HBV) and hepatitis D (HDV) viruses, usually with a more severe clinical outcome when compared to an HBV monoinfection. To date, the real prevalence of HDV infection is underestimated and detection methods are poorly available, especially in more endemic regions. Therefore, a one-step RT-qPCR method for quantification of HDV-RNA was developed. Biological samples were selected between 2017 and 2023 from patients at the Ambulatório Especializado em Hepatites Virais of the Centro de Pesquisa em Medicina Tropical de Rondônia and Serviço de Assistência Especializada and underwent the test developed by this study and a second quantitative RT-qPCR assay. The slope of the initial quantitative assay was - 3.321 with an efficiency of 100.04% and amplification factor equal to 2. Analysis of the repeatability data revealed a Limit of Quantification of 5 copies/reaction and Limit of Detection (95%) of 2.83 copies per reaction. In the diagnostic sensitivity tests, there was an accuracy of 97.37% when compared to the reference test. This assay proved to be highly efficient and reproducible, making it a valuable tool to monitor hepatitis Delta patients and assess the risk of disease progression, as well as the effectiveness of treatment.
乙型肝炎 Delta 病毒(HDV)是一种由乙型肝炎病毒(HBV)和 Delta 肝炎病毒(HDV)感染引起的疾病,与 HBV 单一感染相比,其临床后果通常更为严重。迄今为止,HDV 感染的真实流行率被低估了,而且检测方法也不完善,特别是在感染更为流行的地区。因此,我们开发了一种一步法 RT-qPCR 方法来定量检测 HDV-RNA。本研究选择了 2017 年至 2023 年期间在罗赖马州热带医学研究中心的病毒性肝炎专科门诊和专科医疗服务中心的患者的生物样本,并对这些样本进行了本研究开发的检测以及第二种定量 RT-qPCR 检测。初始定量检测的斜率为-3.321,效率为 100.04%,扩增因子等于 2。对重复性数据的分析显示,检测的定量下限为 5 拷贝/反应,检测限(95%)为每个反应 2.83 拷贝。在诊断灵敏度测试中,与参考测试相比,该检测的准确率为 97.37%。该检测方法证明具有高效性和可重复性,是监测乙型肝炎 Delta 患者、评估疾病进展风险以及治疗效果的有价值的工具。